Biontech Se Sponsored Adr Stock News

This biotech is maturing quickly, and its future won''t look like its past.

This biotech is maturing quickly, and its future won't look like its past.

BioNTech will add 250 jobs to its Marburg, Germany manufacturing site, bringing the total number of positions there to 750, BNN Bloomberg reports.The company also said it

Pfizer (PFE) and BioNTech (BNTX) announce that the first participants in a clinical study on its Omicron-specific COVID-19 vaccine candidate have been dosed.

The CDC is making a push for fourth shots for the immuno-compromised.

NEW YORK , Jan. 26, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MSFT, BNTX, AMD, DDOG, and PENN. Full story available on Benzinga.com

Pfizer Begins Human Trials For New Omicron Vaccine As US Cases Tumble Pfizer and its partner BioNTech just launched the first human trials of their revised COVID vaccine which has been adapted to try and provide better protection against the omicron variant. Shortly after the emergence of omicron in late November, Pfizer and its rivals all promised to produce another generation of vaccines, claiming they could have them ready within three months. So far at least, that timeline appears mostly on track. However, an even more important question for Pfizer might be this: who will even need these jabs when they''re ready, since it looks like the omicron wave numbers will have finally tapered off by the time the trials are completed. At any rate, the two firms said Tuesday they had begun enrolling adults ages 18 to 55 for trials taking place in the US and South Africa. The trials will seek to examine the safety, tolerability and, most importantly, the immune response generated by the new vaccines, per WSJ.

BioNTech (BNTX) stock is rising higher on news it and Pfizer (PFE) can test a new Covid-19 vaccine for Omicron in adults.

BioNTech (BNTX), the German partner of Pfizer (PFE) in COVID-19 vaccine development, says that their plans to manufacture an Omicron-specific vaccine will be subject to how much…

The study will measure the safety and effectiveness of a vaccine specifically tailored to the Omicron variant in adults ages 18 to 55.

Pfizer and BioNTech are testing an omicron-specific form of the COVID-19 vaccine to see if it has more durable protection against coronavirus infection. The original shot still holds against severe disease.

Pfizer Inc (NYSE: Full story available on Benzinga.com

The drugmakers said the study will evaluate the safety and immune response of the new inoculation in up to 1,420 healthy adults ages 18 through 55.

Pfizer (PFE) and BioNTech (BNTX) announced that the first patient was enrolled in their trial for the Omicron-based vaccine candidate.The study designed to test the vaccine as a

Pfizer Inc (NYSE:PFE) and BioNTech say they have signed up the first participants for a clinical trial of a vaccine tailored to target the specific Omicron variant of Covid.  The proposed vaccine wil